May FDA panel to discuss Ebola vax development; U.S., Indian scientists debate swine flu strain's virulence;

> An FDA panel will discuss Ebola vaccine development on May 12. Report

> Scientists in the U.S. and India are battling over the virulence of the latter country's swine flu strain. More

> Immunovaccine is seeking approval to have its common shares trade on the OTCQX(R) Best Marketplace. Release

> NIH's National Institute of Allergy and Infectious Diseases (NIAID) has awarded $16 million to a University of Pennsylvania-led group to develop synthetic DNA vaccines to fight HIV. More

> A new vaccine from China's Yisheng Biopharma for post-exposure treatment of rabies infection has entered human clinical trials. Report

And Finally... India's government is launching a 15-day media campaign to educate the masses on immunization. More

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.